PF-07304814
- Generic Name
- PF-07304814
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N4O9P
- Unique Ingredient Identifier
- XJ51YOB1SC
- Background
PF-07304814 is a small molecule prodrug that targets the 3CL protease (M, which is used by viruses like SARS-CoV-2 to assemble and multiply. Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects. PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled. Now, it is being tested regarding the novel SARS-CoV-2 virus, including studies in conjunction with Remdesivir to treat COVID-19 infection; in vitro data showed synergistic effects on articles published on preprint servers. Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who are hospitalized (NCT04535167).
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 58
- Registration Number
- NCT05780541
- Locations
- πΊπΈ
VA San Diego Healthcare System (Site 074-016), 3350 La Jolla Village Drive, San Diego, California, United States
πΊπΈUniversity of Utah Hospital (Site 211-002), 419 Wakara Way, Suite 207, Salt Lake City, Utah, United States
πΊπΈDuke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT05050682
- Locations
- πΊπΈ
Labcorp Clinical Research Unit, Madison, Wisconsin, United States
Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT04627532
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT04535167
- Locations
- πΊπΈ
UC Davis Medical Center, Sacramento, California, United States
πΊπΈMassachusetts General Hospital Translational and Clinical Research Center, Boston, Massachusetts, United States
π§πͺUniversity Hospital Brugmann, Brussels, Belgium
ACTIV-3: Therapeutics for Inpatients With COVID-19
- Conditions
- Covid19
- Interventions
- Biological: LY3819253Drug: PlaceboBiological: RemdesivirBiological: VIR-7831Biological: BRII-196/BRII-198Biological: AZD7442
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-08-25
- Target Recruit Count
- 2753
- Registration Number
- NCT04501978
- Locations
- πΊπΈ
University of Maryland Medical Center (Site 301-019), 22 South Greene Street, Baltimore, Maryland, United States
πΊπΈRonald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza, Los Angeles, California, United States
πΊπΈLutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard, Fort Wayne, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.